It appears possible to predict renal cell carcinoma (RCC) progression and death using readily available clinical and pathologic features, researchers concluded after conducting a retrospective cohort review involving >3,600 individuals. Participants had clear cell RCC (ccRCC; n=2,726), papillary RCC (papRCC; n=607), or chromophobe RCC (chrRCC; n=222). Investigators developed models based on clinicopathologic features to predict oncologic outcomes. Among the results:
- Progression-free survival c-index was 0.83 for ccRCC, 0.77 for papRCC, and 0.78 for chrRCC.
- Cancer-specific survival c-indexes were 0.86 for ccRCC and 0.83 for papRCC.
- Due to only 22 deaths from RCC, cancer-specific survival was not assessed for chrRCC.
Leibovich B, Lohse C, Cheville J, et al. Predicting oncologic outcomes in renal cell carcinoma after surgery. [Published online ahead of print February 2, 2018]. Eur Urol. doi:10.1016/j.eururo.2018.01.005.
This Week's Must Reads
Oncologists raise access concerns about new mobile technology, Article based on interviews.
Broad opioid legislation advances in Congress, Senate floor debate, Sept. 17, 2018
Early supportive care cuts costs related to curative treatment, Koprowski CD et al. 2018 ASCO Quality Care Symposium, Abstract 142
Employee deductibles outstrip wages, Kaiser Family Foundation, 2018 Employer Health Benefits
The financial burden of metastatic breast cancer, Wheeler SB et al. Quality Care Symposium, Abstract 32
Must Reads in Renal Cell Carcinoma
Obesity tied to higher risk of clear cell RCC, Callahan CL et al. Cancer Epidemiol. 2018 Jul 18. doi: 10.1016/j.canep.2018.07.002
Partial nephrectomy for localized RCC, Cahn D et al. AUA Annual Meeting, Abstract PD07-04
RFA for small renal tumors holds up over long term, Johnson B et al. J Urol. 2018. doi: 10.1016/j.juro.2018.08.045
Pazopanib active in von Hippel-Lindau disease neoplasms, Jonasch E et al. Lancet Oncol. 2018 Sep 17. doi: 10.1016/S1470-2045(18)30487-X
Improved RCC survival attributed to better therapy, not earlier diagnosis, Patel HD et al. Eur Urol Oncol. 2018 Sep 25. doi: 10.1016/j.euo.2018.08.023